Sign in
WithdrawnPhase 1/2

Administration of AdVEGF-All6A+ to Myocardium of Individuals With Diffuse CAD Via Minimally Invasive Surgery

Key facts

Who runs it
Weill Medical College of Cornell University
Trial code
Status
Withdrawn
Phase
Phase 1/2
Started
Dec 2020
Expected to end
Oct 2030
Type of study
Interventional, 5 groups
Treatments tested
  • AdVEGF-All6A+
  • AdNull
Record updated
27 January 2021
Why it stopped
Closure due to lack of funding.

Who can take part

Age
18 years to 90 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 44 criteriaShow less

Who can take part

  • Males and females, age 18 to 90
  • Demonstrable reversible left ventricular ischemia in viable myocardium as assessed by ST segment/T wave abnormalities detected by exercise testing with 99mTc-sestamibi single-photon emission computed tomography (SPECT) prior to and following the exercise test
  • Individuals who have coronary artery disease (CAD) but have angina refractory to medical therapy
  • Individuals who experience angina class II-IV as defined by the Canadian Cardiovascular Society
  • Individuals who have had a coronary angiogram in the prior 6 months demonstrating diffuse coronary artery disease and are not considered to be eligible for coronary artery bypass surgery, stents, or angioplasty, because of the lack of suitable target lesions
  • Individuals must be medically capable of undergoing open thoracotomy
  • Individuals must have neutralizing anti-adenovirus serotype 5 titer ≤160; this criteria is based on the knowledge that some individuals have high anti Ad5 neutralizing antibody titer which may limit efficacy
  • Hematocrit >30%
  • WBC <10,000
  • Normal prothrombin, partial thromboplastin time (excluding IV heparin therapy)
  • Normal liver-related serum parameters
  • Glomerular filtration rate (GFR) > 30 ml/min
  • No evidence of active infection of any types, including adenovirus, hepatitis virus (A, B or C) or human immunodeficiency virus
  • No evidence of central nervous system, major psychiatric, musculoskeletal or immune disorder
  • No allergy to the vehicle used to suspend the virus or contrast materials used in radiographic procedures
  • Fertile or infertile individuals; it will be recommended that fertile individuals utilize barrier birth control measures to prevent pregnancy during and for 2 months following the administration of the vector
  • Individuals not receiving experimental medications or participating in another experimental protocol for at least 4 weeks prior to entry to the study
  • Individuals must be able to exercise for at least 90 seconds but no more than 15 min on a modified Bruce protocol exercise treadmill test while exhibiting angina with concurrent 1 mm horizontal or downsloping ST-segment depression
  • The study individual must be able to undergo the procedures in the protocol
  • Willingness to participate in the study
  • Capable of providing informed consent

Who cannot take part

  • Individuals receiving corticosteroids or other immunosuppressive medications
  • Prior cardiac transplantation
  • Prior participation in cardiac gene and/or cardiac cell therapy
  • Individuals in whom participation in the study would compromise the normal care and expected progression of their disease
  • Individuals with uncontrolled diabetes
  • Diabetic individuals with significantly abnormal ophthalmologic exam (moderate or greater disease severity)
  • Recent (<6 wk) transmural myocardial infarction
  • Unable to undergo cardiac MRI with gadolinium contrast
  • Untreated malignant ventricular arrhythmia
  • Valvular heart disease requiring surgical intervention
  • Uncontrollable asthma or chronic obstructive pulmonary disease (COPD)
  • Greater than first degree heart block or sinus node dysfunction without a functional pacemaker
  • Known hypersensitivity to adenosine
  • Individuals with hypercholesterolemia (LDL above 190 mg/dl or total cholesterol above 240 mg/dl)
  • Evidence of infection defined by elevated white blood cell (WBC) count, temperature >38.5ºC, infiltrate on chest x-ray
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values 2.5 greater than normal limits
  • Preoperative congestive heart failure (New York Heart Association Function Class III or IV or ejection fraction (EF) <25%
  • Individuals who do not meet the inclusion criteria will be unable to participate in the protocol
  • Body mass index >35
  • Recent (<6 wk) cerebral vascular accident
  • Electrocardiograph abnormalities that would interfere with ST-segment analysis
  • Systolic blood pressure less than 90 mmHg
  • Pregnancy or currently lactating

About the trial

What the trial wants to find out

The proposed Phase I/II clinical trial will be used to determine the safety and toxicity of direct administration of the vector AdVEGF-All6A+ to the ischemic myocardium and to generate preliminary evidence regarding whether direct administration of AdVEGF-All6A+ to the ischemic myocardium will induce growth of collateral blood vessels and improve cardiac function. This is a three-part, multinational/multi-center, placebo controlled study.

The 5 groups in the trial

  • Part A, Group 1 - 10^8 puTreatment being tested

    Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10\^8, 10\^9, and 10\^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10\^8 particle units.

    Treatment: AdVEGF-All6A+

  • Part A, Group 2 - 10^9 puTreatment being tested

    Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10\^8, 10\^9, and 10\^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10\^9 particle units.

    Treatment: AdVEGF-All6A+

  • Part A, Group 3 - 10^10 puTreatment being tested

    Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10\^8, 10\^9, and 10\^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10\^10 particle units.

    Treatment: AdVEGF-All6A+

  • Part B, Group 1 - AdVEGF-All6A+Treatment being tested

    Part B (n=32 subjects) is a randomized, double blind, placebo-controlled study that will compare the AdVEGF-All6A+ vector (n=24) to a placebo, AdNull (n=8). Group 1 will receive AdVEGF-All6A+ at the highest tolerable dose determined in Part A.

    Treatment: AdVEGF-All6A+

  • Part B, Group 2 - AdNull placeboTreatment being tested

    Part B (n=32 subjects) is a randomized, double blind, placebo-controlled study that will compare the AdVEGF-All6A+ vector (n=24) to a placebo, AdNull (n=8). Group 2 will receive AdNull, the placebo vector.

    Treatment: AdNull

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase I/II Study, Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector Expressing a cDNA/Genomic Hybrid of Human Vascular Endothelial Growth Factor to the Ischemic Myocardium...
Record updated
27 January 2021